Gabriele Amati

Dr. Gabriele Amati

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
GAGabriele Amati
Gabriele Amati
GSGilda Sandri
Gilda Sandri
ABA. Bertani
A. Bertani
DVDavide Vaccari
Davide Vaccari
APAnnarita Pecchi
Annarita Pecchi
Dilia GiuggioliDilia Giuggioli
Dilia Giuggioli
Magnetic resonance enterography (MRE) is recommended for the assessment of small intestine alterations in Crohn’s disease (CD). Sacroiliac joints (SIJs) imaging has a central role in the early diagnosis of sacroiliitis (SI). MRE can evaluate both acute and structural findings of SIJs. We aimed to assess the prevalence of SI detected by MRE in a cohort of CD patients, and the associations of SI with demographic and clinical features and with intestinal MRE findings. Two hundred patients affected by CD (M:F 1:1, median age 49.5 (22.5) years, median CD duration 4.75 (16.2) years) tested with MRE between 2011 and 2023 were selected. They discontinued tumor necrosis factor α inhibitors (TNFαi) at least 3 months before the MRE execution. Most patients had an ileal CD location (65.0%) and a stricturing behavior of disease (50.0%). Thirty-five percent of patients underwent ileocecal resection. One out of ten patients were treated with at least one TNFαi. Active SI, capsulitis, erosions, sclerosis, and ankylosis were present in 10.5%, 0.5%, 2.0%, 2.5%, and 1.5%, respectively. No significant correlations have been evidenced between the presence of SI and demographic and clinical variables. The presence of an asymmetric hyperenhancement of the bowel wall was instead directly associated with the presence of SI (OR 8.61, 95% CI 1.47–50.4, p = 0.017). In this study, subclinical SI is a frequent finding in CD patients being present in one out of ten MRE examination. This phenomenon was significantly associated with asymmetric mural enhancement, a specific CD intestinal lesion at MRE.

20 January 2025 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
GSGilda Sandri
Gilda Sandri
GAGabriele Amati
Gabriele Amati
ASAmelia Spinella
Amelia Spinella
PNPatrizia Natali
Patrizia Natali
DDDaria Debbia
Daria Debbia
Dilia GiuggioliDilia Giuggioli
Dilia Giuggioli
: The aims of this study were to investigate the prevalence of cryofibrinogenemia in a cohort of patients with systemic sclerosis (SSc) regardless of clinical manifestations, who were admitted to our hospital and determine the associations among CF positivity, disease features and ongoing therapies. This was a monocentric and retrospective study. The inclusion criteria were a diagnosis of SSc (according to the ACR/EULAR 2013 classification criteria), regular administration of i.v. prostanoids, and CF testing between February 2020 and February 2022. Data on demographic, clinical, and immunological features and ongoing treatments were retrospectively collected. Categorical data were compared with the chi-square test or Fisher’s exact test, while quantitative variables comparisons were carried out with Student’s t test or Mann‒Whitney test. In total, 101 SSc patients were ultimately enrolled. The majority of patients were female (92.1%) and had the limited cutaneous form of SSc (81.2%). CF positivity was observed in 69.3% of the patients, whereas only 9% presented cryoglobulins and CF. CF positivity was negatively associated to RNAP3 antibodies (p = 0.027). No direct associations with specific clinical phenotypes were observed. No associations with immunosuppressive treatments were identified, however a positive association with nifedipine administration (p = 0.040), and a negative association with endothelin receptor antagonists (ERAs) plus phosphodiesterase-5 (PDE5) inhibitors regimen (p = 0.031) were observed. Macitentan administration was also associated to CF cryocrit ≥ 1% (p = 0.045). Among patients who were not treated with ERAs, an estimated pulmonary artery systolic pressure ≥ 30 mmHg was significantly associated with CF positivity (p = 0.025). Moreover, a cryocrit ≥3% was associated with a relative risk of 3.44 (95% CI 1.26–9.39, p = 0.016) for digital amputation and 5.17 (95% CI 1.18–22.6, p = 0.029) for death. Isolated CF is a frequent phenomenon observed in SSc patients and is associated with a higher administration of vasoactive drugs, probably identifying a SSc clinical phenotype with a more severe microvascular involvement. Moreover, a higher cryocrit is associated with an increased risk of death and digital amputations. Screening SSc patients for CF would represent an opportunity to provide better therapeutic approaches by anticipating ERA administration in an earlier phase, thereby preventing the manifestation of severe microvascular involvement. Key Points• Cryofibrinogen is a cryoprotein that can cause microangiopathic damage.• Isolated cryofibrinogenemia is common in patients with systemic sclerosis.• SSc patients should be tested for cryofibrinogen because a high cryocrit (≥ 3%) is associated with death and/or digital amputation due to necrosis.• Cryofibrinogen is associated with indirect markers of pulmonary arterial hypertension in patients not treated with endothelin receptor agonists (ERAs).• ERAs could play a role in preventing cryofibrinogen damage.

4 December 2025 in Modern Rheumatology
Verified
Journal Article
Open access
GCGiovanni Ciancio
Giovanni Ciancio
BMBeatrice Maranini
Beatrice Maranini
GSGilda Sandri
Gilda Sandri
GAGabriele Amati
Gabriele Amati
ABAlessandra Bortoluzzi
Alessandra Bortoluzzi
Dilia GiuggioliDilia Giuggioli
Dilia Giuggioli
Obesity and metabolic syndrome play a significant role in the complexity of chronic inflammatory arthritis. By promoting systemic inflammation and altering immune responses, these conditions can amplify joint-related symptoms, such as pain, synovitis, and enthesitis. This inflammatory and mechanical burden complicates clinical evaluation, as traditional disease activity scores may be skewed by excess weight, leading to inaccurate assessments. Imaging techniques like musculoskeletal ultrasound (MSUS) offer a promising tool to detect subclinical inflammation and improve diagnostic accuracy. This review examines the role of MSUS in the management of obese patients with inflammatory arthritis. We explore how MSUS can be leveraged to detect subclinical inflammation, improve diagnostic accuracy, and guide more effective management strategies. We also discuss the limitations of MSUS in this patient population, including the impact of excessive adipose tissue on image quality and the need for standardized protocols.